HUP0102853A1 - Moraxella catarrhalis-ból származó vegyületek - Google Patents
Moraxella catarrhalis-ból származó vegyületekInfo
- Publication number
- HUP0102853A1 HUP0102853A1 HU0102853A HUP0102853A HUP0102853A1 HU P0102853 A1 HUP0102853 A1 HU P0102853A1 HU 0102853 A HU0102853 A HU 0102853A HU P0102853 A HUP0102853 A HU P0102853A HU P0102853 A1 HUP0102853 A1 HU P0102853A1
- Authority
- HU
- Hungary
- Prior art keywords
- moraxella
- treatment
- well
- moraxella catarrhalis
- compounds
- Prior art date
Links
- 241000588655 Moraxella catarrhalis Species 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 241000588621 Moraxella Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány tárgyát képezik izolált polipeptidek, amelyek Moraxellacatarrhalis fertőzés elleni oltóanyagokban alkalmazhatók, közelebbrőlBASB020 polipeptidek, ellenük készült antitestek, továbbá apolipeptideket kódoló izolált polinukleotidok, az azokat tartalmazóexpressziós vektorok és élő mikroorganizmusok, továbbá Moraxellacatarrhalis betegségben szenvedő emberi személyek kezelésére alkalmasterápiás készítmények és oltóanyagok. A találmány szerinti megoldásMoraxella catarrhalis okozta betegségek diagnosztizálásában,megelőzésében és kezelésében alkalmazható. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9810285.8A GB9810285D0 (en) | 1998-05-13 | 1998-05-13 | Novel compounds |
| PCT/EP1999/003257 WO1999058684A2 (en) | 1998-05-13 | 1999-05-07 | Compounds from moraxella catarrhalis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0102853A1 true HUP0102853A1 (hu) | 2001-11-28 |
| HUP0102853A3 HUP0102853A3 (en) | 2008-04-28 |
Family
ID=10831997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102853A HUP0102853A3 (en) | 1998-05-13 | 1999-05-07 | Compounds from moraxella catarrhalis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7122197B1 (hu) |
| EP (1) | EP1078064B1 (hu) |
| JP (1) | JP4503175B2 (hu) |
| KR (1) | KR100610448B1 (hu) |
| CN (3) | CN1210401C (hu) |
| AT (1) | ATE303442T1 (hu) |
| AU (1) | AU737196B2 (hu) |
| BR (1) | BR9911773A (hu) |
| CA (1) | CA2328502A1 (hu) |
| CZ (1) | CZ298227B6 (hu) |
| DE (1) | DE69927017T2 (hu) |
| DK (1) | DK1078064T3 (hu) |
| ES (1) | ES2247803T3 (hu) |
| GB (1) | GB9810285D0 (hu) |
| HK (1) | HK1036299A1 (hu) |
| HU (1) | HUP0102853A3 (hu) |
| IL (2) | IL139612A0 (hu) |
| NO (1) | NO330169B1 (hu) |
| NZ (1) | NZ508322A (hu) |
| PL (1) | PL199497B1 (hu) |
| TR (1) | TR200003345T2 (hu) |
| WO (1) | WO1999058684A2 (hu) |
| ZA (1) | ZA200006522B (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| SI2255826T1 (sl) | 2002-08-02 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CN111003884B (zh) * | 2019-12-05 | 2021-12-31 | 浙江海洋大学 | 重金属污水处理设备及处理方法 |
| CN114703214A (zh) * | 2022-03-03 | 2022-07-05 | 南京吉芮康生物科技研究院有限公司 | 一种抗丢失时空可控表达的新型质粒及其应用 |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552146A (en) * | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| US5712118A (en) | 1993-09-29 | 1998-01-27 | Research Foundation Of State University Of New York | Vaccine for branhamella catarrhalis |
| US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US6607731B1 (en) * | 1995-09-22 | 2003-08-19 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| US6090576A (en) * | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
| US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| AU740481B2 (en) * | 1996-08-12 | 2001-11-08 | Board Of Regents, The University Of Texas System | Defining epitopes of the outer membrane protein CopB of moraxella catarrhalis |
| US6673910B1 (en) | 1999-04-08 | 2004-01-06 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics |
| WO2000078968A2 (en) | 1999-06-18 | 2000-12-28 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
-
1998
- 1998-05-13 GB GBGB9810285.8A patent/GB9810285D0/en not_active Ceased
-
1999
- 1999-05-07 AU AU41421/99A patent/AU737196B2/en not_active Ceased
- 1999-05-07 CN CNB998085545A patent/CN1210401C/zh not_active Expired - Fee Related
- 1999-05-07 EP EP99924948A patent/EP1078064B1/en not_active Expired - Lifetime
- 1999-05-07 AT AT99924948T patent/ATE303442T1/de active
- 1999-05-07 DE DE69927017T patent/DE69927017T2/de not_active Expired - Lifetime
- 1999-05-07 TR TR2000/03345T patent/TR200003345T2/xx unknown
- 1999-05-07 DK DK99924948T patent/DK1078064T3/da active
- 1999-05-07 KR KR1020007012705A patent/KR100610448B1/ko not_active IP Right Cessation
- 1999-05-07 PL PL344792A patent/PL199497B1/pl not_active IP Right Cessation
- 1999-05-07 BR BR9911773-8A patent/BR9911773A/pt not_active Application Discontinuation
- 1999-05-07 IL IL13961299A patent/IL139612A0/xx active IP Right Grant
- 1999-05-07 JP JP2000548475A patent/JP4503175B2/ja not_active Expired - Fee Related
- 1999-05-07 CZ CZ20004203A patent/CZ298227B6/cs not_active IP Right Cessation
- 1999-05-07 CA CA002328502A patent/CA2328502A1/en not_active Abandoned
- 1999-05-07 ES ES99924948T patent/ES2247803T3/es not_active Expired - Lifetime
- 1999-05-07 CN CNB2005100746588A patent/CN100484956C/zh not_active Expired - Fee Related
- 1999-05-07 NZ NZ508322A patent/NZ508322A/xx unknown
- 1999-05-07 CN CNA2006100997400A patent/CN1876679A/zh active Pending
- 1999-05-07 US US09/700,228 patent/US7122197B1/en not_active Expired - Fee Related
- 1999-05-07 WO PCT/EP1999/003257 patent/WO1999058684A2/en active IP Right Grant
- 1999-05-07 HU HU0102853A patent/HUP0102853A3/hu unknown
-
2000
- 2000-11-10 IL IL139612A patent/IL139612A/en not_active IP Right Cessation
- 2000-11-10 NO NO20005697A patent/NO330169B1/no not_active IP Right Cessation
- 2000-11-10 ZA ZA200006522A patent/ZA200006522B/en unknown
-
2001
- 2001-08-13 HK HK01105646A patent/HK1036299A1/xx not_active IP Right Cessation
-
2006
- 2006-02-28 US US11/364,212 patent/US20060147462A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902327A2 (hu) | Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk | |
| HUP0102479A2 (hu) | Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek | |
| HUP0301740A2 (hu) | Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások | |
| RU94038043A (ru) | Применение замещенных производных аденина для лечения множественного склероза | |
| PT912898E (pt) | Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg | |
| EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
| DE69721006D1 (de) | Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen | |
| GB9224584D0 (en) | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases | |
| HUP0203035A2 (hu) | Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások | |
| DE69922261D1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| KR930702026A (ko) | 자기항원의 경구 투여에 의한 자기면역 질병의 치료 | |
| HUP0401903A2 (hu) | Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére | |
| ATE510562T1 (de) | Anti-ailim antikörper zur behandlung von crohn's | |
| HUP9901908A2 (hu) | p16 Expressziós konstrukciók és alkalmazásuk rákterápiában | |
| EP0674661A4 (en) | TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS. | |
| HUP0100012A2 (hu) | Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére | |
| DE3685853D1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
| HUP0102853A1 (hu) | Moraxella catarrhalis-ból származó vegyületek | |
| WO2002046221A3 (en) | Human protein differentially expressed in alzheimer's disease's brain | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| HUP0003116A2 (hu) | Béta-amiloid-peptid-kötő fehérjék és az őket kódoló polinukleotidok | |
| DE60330914D1 (de) | Arzneimittel mit shikonin als wirkstoff | |
| HUP0104743A2 (hu) | Az L. infantum proteinjeinek antigéndeterminánsait kódoló kiméragén | |
| MXPA04001986A (es) | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. | |
| HUP0200162A2 (hu) | Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |